The PennZone

PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone

• Fig Lehigh Valley Celebrates 50th Edition With Summer Launch Party at the Americus Hotel
• Make America French Again Launches National Campaign
• RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
• New Children's Book Teaches Kids the Lesson Its Author Spent a Career Learning: Your Worth Doesn't Need Permission
• Proper Sky Named to the 2026 MSP 501

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone

• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
• Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
• Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
• OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).